dc.contributor.advisor | Hernández, Edith del Carmen | |
dc.contributor.advisor | Rodríguez Panduro, Mauricio Humberto | |
dc.contributor.author | Buitrago Mejía, Lorena | |
dc.date.accessioned | 2022-03-07T20:25:15Z | |
dc.date.available | 2022-03-07T20:25:15Z | |
dc.date.issued | 2018-11 | |
dc.identifier.uri | https://repositorio.unicolmayor.edu.co/handle/unicolmayor/4781 | |
dc.description.abstract | Los virus oncolíticos son virus naturales o genéticamente modificados que
tienen la capacidad de infectar las células cancerígenas, replicarse dentro de
ellas causando su destrucción y de esta manera estimular la respuesta
antitumoral del huésped.
Por otra parte el cáncer de mama es de gran importancia en salud pública con
un número de casos que crece a través del tiempo. Dentro de su clasificación
se encuentra el cáncer de mama HER2 positivo que es de mal pronóstico,
agresivo y de alto grado histológico alto, que incrementa con el diagnóstico
tardío.
En esta revisión bibliográfica se recopiló información significativa sobre los
virus oncolíticos y su posible empleabilidad en el tratamiento de cáncer de
mama, descripción de su potencial, y los diferentes mecanismos de acción que
los hacen agentes biológicos excelentes en terapias anti cáncer. Los resultados
arrojan que la mayoría de investigaciones con virus oncolíticos se realizan en
EEUU, y los virus más empleados para ensayos cáncer de mama son el virus
del herpes simplex con un 31% y el adenovirus con un 13%; estos virus
modificados permiten activar el sistema inmune, aumentar la selectividad
hacia la célula tumoral, promover la creación de anticuerpos contra un blanco
especifico, ser útiles como marcadores de seguimiento, entre otros. Con esta
revisión de literatura se espera motivar a los investigadores a incrementar sus
ensayos no solo con otros virus oncolíticos sino también con diferentes blancos
terapéuticos en el cáncer de mama que permitan ampliar las opciones
terapéuticas en los pacientes, en especial el cáncer de mama HER2 positivo.
Que si bien, de acuerdo a esta revisión para cáncer de mama HER2 positivo
no hay una muestra representativa de experimentos que ayuden a concluir si
es o no factible una alternativa terapéutica con virus oncolíticos. | spa |
dc.description.tableofcontents | 1. INTRODUCCIÓN 1
2. DESCRIPCIÓN DEL PROYECTO 2
2.1 Planteamiento del Problema 2
2.2 Justificación 3
3. OBJETIVOS 4
3.1 GENERAL 4
3.2 ESPECÍFICOS 4
4. ANTECEDENTES 5
5. MARCO TEORICO 8
5.1 Virus oncolíticos. 8
5.1.1 Mecanismo de acción de los virus oncolíticos 9
5.1.2 Usos actuales de los virus oncolíticos 12
5.2 Definición de cáncer 16
5.3 El Cáncer de mama 18
5.3.1 Definición del cáncer de mama 18
5.3.2 Epidemiología del Cáncer de mama 18
5.3.3 Clasificación molecular del Cáncer de mama 22
5.3.4 Cáncer de mama HER2 Positivo 23
5.3.5 Tratamiento para el Cáncer de mama 24
5.3.5.1Tratamiento farmacológico tradicional 24
5.3.5.2Tratamiento con virus oncolíticos 26
6. METODOLOGÍA 29
6.1 Diseño Metodológico 29
6.2 Procedimientos 29
6.2.1 Búsqueda de la información 29
6.2.2 Recolección de la información 29
6.2.3 Análisis de la información 29
7. RESULTADOS 30
7.1 Año de Publicación 30
7.2 Tipo de publicación 31
7.3 País de publicación 32
7.4 Tema de las publicaciones 33
7.5 Virus empleados en investigación para el tratamiento del cáncer 34
7.6 Uso de los virus oncolíticos en Cáncer de mama y otros tipos de
cáncer 35
7.7 Tipos de virus oncolíticos empleados en investigación para cáncer de
mama 36
7.8 Mecanismos de acción de los virus del herpes simplex para cáncer de
mama 37
7.9 Mecanismos de acción de los adenovirus para cáncer de mama 39
8. DISCUSIÓN 41
9. CONCLUSIONES 44 | spa |
dc.format.extent | 55p. | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | spa | spa |
dc.publisher | Universidad Colegio Mayor de Cundinamarca | spa |
dc.rights | Derechos Reservados - Universidad Colegio Mayor de Cundinamarca, 2018 | spa |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/4.0/ | spa |
dc.title | Revisión de literatura sobre los virus con posible capacidad oncolítica para el tratamiento del cáncer de mama Her2 positivo | spa |
dc.type | Trabajo de grado - Pregrado | spa |
dc.description.degreelevel | Pregrado | spa |
dc.description.degreename | Bacteriólogo(a) y Laboratorista Clínico | spa |
dc.identifier.barcode | 58661 | |
dc.publisher.faculty | Facultad de Ciencias de la Salud | spa |
dc.publisher.place | Bogotá D.C | spa |
dc.publisher.program | Bacteriología y Laboratorio Clínico | spa |
dc.relation.references | MINSALUD. Cáncer de mama, una enfermedad en ascenso en Colombia
[Internet]. 2014 [cited 2018 Mar 20]. Available from:
https://www.minsalud.gov.co/Paginas/-Cancer-de-mama,-unaenfermedad-en-ascenso-en-Colombia.aspx | spa |
dc.relation.references | Viviana Y, Márquez A, Balcázar IB, Aristizábal FA. Tratamiento de cáncer de
seno y farmacogenética Treatment of breast cancer and pharmacogenetics.
Rev Colomb Biotecnol [Internet]. 2016 [cited 2018 Feb 20]; Available from:
http://www.scielo.org.co/pdf/biote/v18n1/v18n1a14.pdf | spa |
dc.relation.references | McCafferty MPJ, Healy NA, Kerin MJ. Breast cancer subtypes and molecular
biomarkers. Diagnostic Histopathol [Internet]. 2009 Oct 1 [cited 2017 Oct
26];15(10):485–9. Available from:
http://linkinghub.elsevier.com/retrieve/pii/S1756231709001455 | spa |
dc.relation.references | D MK, S A-D. Efectos del Trastuzumab como Terapia Coadyuvante para
Pacientes con Cáncer de Mama Her2-Positivo: Una Revisión Sistemática.
Arch Med [Internet]. 2017 Aug 5 [cited 2017 Oct 27];13(3). Available from:
http://www.archivosdemedicina.com/medicina-de-familia/efectos-deltrastuzumab-como-terapia-coadyuvante-para-pacientes-con-caacutencerde-mama-her2positivo-una-revisioacuten-sistemaacut.php?aid=20055 | spa |
dc.relation.references | Garnock-Jones KP, Keating GM, Scott LJ. Trastuzumab. Drugs [Internet].
2010 Jan [cited 2017 Oct 27];70(2):215–39. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/20108993 | spa |
dc.relation.references | Arrese I, González P, Miranda P, Perez-Nuñez P, Pascual B, Lobato RD.
Tratamiento de los gliomas mediante virus oncolíticos: revisión de la
literatura. Neurocirugia. 2005;16:158–68. | spa |
dc.relation.references | Rodríguez L. CAGF. LA PROTEÍNA VIRAL VP6 DE ROTAVIRUS
COINMUNOPRECIPITA CON HSC70 EN CÉLULAS MA104. 2006; | spa |
dc.relation.references | Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic
engineering. Mol Ther [Internet]. 2007;15(4):651–9. Available from:
http://dx.doi.org/10.1038/sj.mt.6300108 | spa |
dc.relation.references | jaime R. merchan barros, jun j. madera merchan sheila p. auz ramirez.
viroterapia mediante virus oncoliticos en tumores sólidos [Internet]. 2011.
Available from: http://medpre.med.ec/secciones/medicina/1
revista/Viroterapia mediante virus oncoliticos en tumores solidos.pdf | spa |
dc.relation.references | Ramos Guette PL. Características clínicas y mortalidad en pacientes con
cáncer de mama avanzado (estados iiia iiib iiic) en colombia, clínica
oncocare, 2003–2012. Rev Colomb Cancerol [Internet]. 2013 Dec 1 [cited
2018 Mar 8];17(4):180–1. Available from:
https://www.sciencedirect.com/science/article/pii/S0123901513702002 | spa |
dc.relation.references | Rodríguez JA, Martínez LM, Cruz N, Cómbita AL. Terapia génica para el
tratamiento del cáncer. Rev Colomb Cancerol [Internet]. 2014;18(1):27–
40. Available from:
http://linkinghub.elsevier.com/retrieve/pii/S0123901514702227 | spa |
dc.relation.references | Cho M. Bioinformatics research on the specificity and safety of oncolytic
viruses. 2015 [cited 2017 Oct 13]; Available from: http://sspace.snu.ac.kr/handle/10371/128348 | spa |
dc.relation.references | Dutilh BE, Reyes A, Hall RJ, Whiteson KL. Editorial: Virus Discovery by
Metagenomics: The (Im)possibilities. Front Microbiol [Internet]. 2017 Sep
8 [cited 2017 Sep 26];8:1710. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/28943867 | spa |
dc.relation.references | Lawler SE, Speranza M-C, Cho C-F, Chiocca EA, RL M, BD L, et al. Oncolytic
Viruses in Cancer Treatment. JAMA Oncol [Internet]. 2016;2(12):938–50.
Available from:
http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2
016.2064 | spa |
dc.relation.references | Suryawanshi YR, Zhang T, Essani K. Oncolytic viruses: emerging options for
the treatment of breast cancer. Med Oncol [Internet]. 2017 Mar 9 [cited
2018 Mar 15];34(3):43. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/28185165 | spa |
dc.relation.references | Miest TS, Cattaneo R. New viruses for cancer therapy: meeting clinical
needs. Nat Rev Microbiol [Internet]. 2014 Jan 2 [cited 2018 Aug
13];12(1):23–34. Available from:
http://www.nature.com/articles/nrmicro3140 | spa |
dc.relation.references | Release FDAN, Release FI. FDA approves first of its kind product for the
treatment of melanoma. 2016;1–4. Available from:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm54
8278.htm | spa |
dc.relation.references | Bramante S, Koski A, Liikanen I, Vassilev L, Oksanen M, Siurala M, et al.
Oncolytic virotherapy for treatment of breast cancer, including triplenegative breast cancer. Oncoimmunology [Internet]. 2016 Feb [cited 2018
Aug 20];5(2):e1078057. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27057453 | spa |
dc.relation.references | Talimogene laherparepvec for melanoma. Aust Prescr [Internet]. 2017 Feb
[cited 2018 Mar 15];40(1):38–9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/28246438 | spa |
dc.relation.references | Hummel JL, Safroneeva E, Mossman KL. The role of ICP0-Null HSV-1 and
interferon signaling defects in the effective treatment of breast
adenocarcinoma. Mol Ther [Internet]. 2005 Dec [cited 2018 Aug
22];12(6):1101–10. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/16140040 | spa |
dc.relation.references | Sahin TT, Kasuya H, Nomura N, Shikano T, Yamamura K, Gewen T, et al.
Impact of novel oncolytic virus HF10 on cellular components of the tumor
microenviroment in patients with recurrent breast cancer. Cancer Gene Ther
[Internet]. 2012 Apr 23 [cited 2018 Mar 16];19(4):229–37. Available from:
http://www.nature.com/articles/cgt201180 | spa |
dc.relation.references | Thomas DL, Fraser NW. HSV-1 therapy of primary tumors reduces the
number of metastases in an immune-competent model of metastatic breast
cancer. Mol Ther [Internet]. 2003 Oct 1 [cited 2018 Jul 29];8(4):543–51.
Available from:
https://www.sciencedirect.com/science/article/pii/S1525001603002363 | spa |
dc.relation.references | Cody JJ, Markert JM, Hurst DR. Histone Deacetylase Inhibitors Improve the
Replication of Oncolytic Herpes Simplex Virus in Breast Cancer Cells. PLoS
One [Internet]. 2014 [cited 2018 Jul 29];9(3):e92919. Available from:
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0092919 | spa |
dc.relation.references | Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, et al. A combinational
therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for
breast cancer brain metastases. Oncotarget [Internet]. 2016 May 10 [cited
2018 Jul 29];7(19):27764–77. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27050072 | spa |
dc.relation.references | Walker JD, Sehgal I, Kousoulas KG. Oncolytic herpes simplex virus 1
encoding 15-prostaglandin dehydrogenase mitigates immune suppression
and reduces ectopic primary and metastatic breast cancer in mice. J Virol
[Internet]. 2011 Jul [cited 2018 Aug 22];85(14):7363–71. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/21543507 | spa |
dc.relation.references | Fasullo M, Burch A, Britton A. Hypoxia enhances the replication of oncolytic
herpes simplex virus in p53- breast cancer cells. Cell Cycle [Internet]. 2009
Jul 15 [cited 2018 Jul 29];8(14):2194–7. Available from:
http://www.tandfonline.com/doi/abs/10.4161/cc.8.14.8934 | spa |
dc.relation.references | Pourchet A, Fuhrmann SR, Pilones KA, Demaria S, Frey AB, Mulvey M, et al.
CD8+ T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.
EBioMedicine [Internet]. 2016 Mar 1 [cited 2018 Aug 20];5:59–67.
Available from:
https://www.sciencedirect.com/science/article/pii/S2352396416300184 | spa |
dc.relation.references | Tan G, Kasuya H, Sahin TT, Yamamura K, Wu Z, Koide Y, et al. Combination
therapy of oncolytic herpes simplex virus HF10 and bevacizumab against
experimental model of human breast carcinoma xenograft. Int J Cancer
[Internet]. 2015 Apr 1 [cited 2018 Aug 20];136(7):1718–30. Available
from: http://doi.wiley.com/10.1002/ijc.29163 | spa |
dc.relation.references | Chiocca EA. Oncolytic viruses. Invest New Drugs [Internet].
2002;17(4):375–86. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/12459732 | spa |
dc.relation.references | Hirvinen M, Rajecki M, Kapanen M, Parviainen S, Rouvinen-Lagerström N,
Diaconu I, et al. Immunological Effects of a Tumor Necrosis Factor Alpha–
Armed Oncolytic Adenovirus. Hum Gene Ther [Internet]. 2015 Mar 4 [cited
2018 Aug 20];26(3):134–44. Available from:
http://www.liebertpub.com/doi/10.1089/hum.2014.069 | spa |
dc.relation.references | 1Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence
LM, et al. Therapeutics, Targets, and Chemical Biology Oncolytic Adenovirus
and Tumor-Targeting Immune Modulatory Therapy Improve Autologous
Cancer Vaccination. Cancer Res [Internet]. 2017 [cited 2018 Aug
20];77(14). Available from: http://cancerres.aacrjournals.org/ | spa |
dc.relation.references | Hock K, Laengle J, Kuznetsova I, Egorov A, Hegedus B, Dome B, et al.
Oncolytic influenza A virus expressing interleukin-15 decreases tumor
growth in vivo. Surgery [Internet]. 2017 Mar 1 [cited 2018 Jul
29];161(3):735–46. Available from:
https://www.sciencedirect.com/science/article/pii/S0039606016304809 | spa |
dc.relation.references | Stoff-Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, et al.
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung
metastases of breast carcinoma. Breast Cancer Res Treat [Internet]. 2007
Aug 31 [cited 2018 Jul 29];105(2):157–67. Available from:
http://link.springer.com/10.1007/s10549-006-9449-8 | spa |
dc.relation.references | Bazan-Peregrino M, Carlisle RC, Hernandez-Alcoceba R, Iggo R, Homicsko K,
Fisher KD, et al. Comparison of Molecular Strategies for Breast Cancer
Virotherapy Using Oncolytic Adenovirus. https://home.liebertpub.com/hum
[Internet]. 2008 Sep 16 [cited 2018 Jul 29]; Available from:
https://www.liebertpub.com/doi/abs/10.1089/hum.2008.047 | spa |
dc.relation.references | Gomes EM, Rodrigues MS, Phadke AP, Butcher LD, Starling C, Chen S, et al.
Antitumor Activity of an Oncolytic Adenoviral-CD40 Ligand (CD154)
Transgene Construct in Human Breast Cancer Cells. 2009 [cited 2018 Jul
29]; Available from: www.aacrjournals.org | spa |
dc.relation.references | Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, et al. Use of
an oncolytic vaccinia virus for the treatment of canine breast cancer in nude
mice: preclinical development of a therapeutic agent. Cancer Gene Ther
[Internet]. 2009 Apr 24 [cited 2018 Jul 29];16(4):320–8. Available from:
http://www.nature.com/articles/cgt200887 | spa |
dc.relation.references | Yoo SY, Bang SY, Jeong S-N, Kang DH, Heo J. A cancer-favoring oncolytic
vaccinia virus shows enhanced suppression of stem-cell like colon cancer.
Oncotarget [Internet]. 2016 Mar 29 [cited 2018 Aug 20];7(13):16479–89.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/26918725 | spa |
dc.relation.references | Gholami S, Marano A, Chen NG, Aguilar RJ, Frentzen A, Chen C-H, et al. A
novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic
effects against triple-negative breast cancer. Breast Cancer Res Treat
[Internet]. 2014 Dec 13 [cited 2018 Aug 20];148(3):489–99. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/25391896 | spa |
dc.relation.references | Sugiyama T, Yoneda M, Kuraishi T, Hattori S, Inoue Y, Sato H, et al. Measles
virus selectively blind to signaling lymphocyte activation molecule as a novel
oncolytic virus for breast cancer treatment. Gene Ther [Internet]. 2013 Mar
21 [cited 2018 Jul 29];20(3):338–47. Available from:
http://www.nature.com/articles/gt201244 | spa |
dc.relation.references | Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, et al.
Demonstration of anti-tumor activity of oncolytic measles virus strains in a
malignant pleural effusion breast cancer model. Breast Cancer Res Treat
[Internet]. 2010 Aug 6 [cited 2018 Jul 29];122(3):745–54. Available from:
http://link.springer.com/10.1007/s10549-009-0602-z | spa |
dc.relation.references | McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM, et al.
A measles virus vaccine strain derivative as a novel oncolytic agent against
breast cancer. Breast Cancer Res Treat [Internet]. 2006 Sep 27 [cited 2018
Jul 29];99(2):177–84. Available from:
http://link.springer.com/10.1007/s10549-006-9200-5 | spa |
dc.relation.references | Asada T. Treatment of human cancer with mumps virus. Cancer [Internet].
1974 Dec [cited 2018 Aug 7];34(6):1907–28. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/4611607 | spa |
dc.relation.references | Ammayappan A, Russell SJ, Federspiel MJ. Recombinant mumps virus as a
cancer therapeutic agent. Mol Ther - Oncolytics [Internet]. 2016 Jan 1 [cited
2018 Jul 29];3. Available from:
https://www.sciencedirect.com/science/article/pii/S2372770517300128 | spa |
dc.relation.references | Le Boeuf F, Gebremeskel S, McMullen N, He H, Greenshields AL, Hoskin DW,
et al. Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic
Virotherapy in Primary and Metastatic Tumor Models. Mol Ther - Oncolytics
[Internet]. 2017 Sep 15 [cited 2018 Jul 29];6:80–9. Available from:
https://www.sciencedirect.com/science/article/pii/S237277051730030X | spa |
dc.relation.references | Olagnier D, Lababidi RR, Hadj SB, Sze A, Liu Y, Naidu SD, et al. Activation
of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via
Autophagy-Driven Suppression of Antiviral Immunity. Mol Ther [Internet].
2017 Aug 2 [cited 2018 Aug 20];25(8):1900–16. Available from:
https://www.sciencedirect.com/science/article/pii/S152500161730206X | spa |
dc.relation.references | Bourgeois-Daigneault M-C, Roy DG, Falls T, Twumasi-Boateng K, StGermain LE, Marguerie M, et al. Oncolytic vesicular stomatitis virus
expressing interferon-σ has enhanced therapeutic activity. Mol Ther -
Oncolytics [Internet]. 2016 Jan 1 [cited 2018 Aug 20];3. Available from:
https://www.sciencedirect.com/science/article/pii/S237277051630033X | spa |
dc.relation.references | Platonov ME, Borovjagin A V., Kaverina N, Xiao T, Kadagidze Z, Lesniak M,
et al. KISS1 tumor suppressor restricts angiogenesis of breast cancer brain
metastases and sensitizes them to oncolytic virotherapy in vitro. Cancer
Lett [Internet]. 2018 Mar 28 [cited 2018 Jul 29];417:75–88. Available from:
https://www.sciencedirect.com/science/article/pii/S0304383517307966 | spa |
dc.relation.references | Sakhawat A, Liu Y, Ma L, Muhammad T, Wang S, Zhang L, et al. Upregulation
of Coxsackie Adenovirus Receptor Sensitizes Cisplatin-Resistant Lung
Cancer Cells to CRAd-Induced Inhibition. J Cancer [Internet]. 2017 [cited
2018 Aug 20];8(8):1425–32. Available from:
http://www.jcancer.org/v08p1425.htm | spa |
dc.relation.references | Menezes ME, Shen X-N, Das SK, Emdad L, Guo C, Yuan F, et al. decot
functions as a tumor suppressor gene in vivo in transgenic mouse models
of breast cancer. Oncotarget [Internet]. 2015 Nov 10 [cited 2018 Aug
20];6(35):36928–42. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/26474456 | spa |
dc.relation.references | Liikanen I, Tähtinen S, Guse K, Gutmann T, Savola P, Oksanen M, et al.
Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for
Treatment of HER2-Positive Cancer. Mol Cancer Ther [Internet]. 2016 Aug
17 [cited 2018 Aug 20];15(9):2259–69. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27458139 | spa |
dc.relation.references | Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C, et
al. Paclitaxel resistance increases oncolytic adenovirus efficacy via
upregulated CAR expression and dysfunctional cell cycle control. Mol Oncol
[Internet]. 2015 Apr 1 [cited 2018 Aug 20];9(4):791–805. Available from:
http://doi.wiley.com/10.1016/j.molonc.2014.12.007 | spa |
dc.relation.references | Tan KX, Danquah MK, Sidhu A, Ongkudon CM, Lau SY. Towards targeted
cancer therapy: Aptamer or oncolytic virus? Eur J Pharm Sci [Internet].
2017 Jan 1 [cited 2018 Jul 29];96:8–19. Available from:
https://www.sciencedirect.com/science/article/pii/S0928098716303505 | spa |
dc.relation.references | Sanchez C. conociendo y comprendiendo la célula cancerosa: fisiopatología
del cáncer. Rev medica Clin condes [Internet]. 2013;24:553–62. Available
from: https://www.clinicalascondes.cl/Dev_CLC/media/Imagenes/PDF
revista médica/2013/4 julio/REV--MED--CLIN.-CONDES---2013;-24(4)-
WEB.pdf | spa |
dc.relation.references | Cooper GM, Hausman RE. La célula [Internet]. Marbán; 2014 [cited 2018
Aug 7]. Available from:
https://www.librerianacional.com/pagina=producto&libro=315210&autor=
8832&editorial=2507 | spa |
dc.relation.references | María Teresa Martín de Civetta, MC; Julio Domingo Civetta M. Carcinogénesis
[Internet]. Vol. 53, Salud Pública de México. salud publica de mexico; 2011
[cited 2018 Mar 20]. 405-414 p. Available from:
http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-
36342011000500008 | spa |
dc.relation.references | Hernández DE. BIOLOGÍA DEL CÁNCER DE MAMA De interés en oncología.
Rev Venez Oncol [Internet]. 2016 [cited 2018 Mar 20];28(3):188–200.
Available from: http://www.redalyc.org/pdf/3756/375645930010.pdf | spa |
dc.relation.references | Pardo Ramos C, Cendales Duarte R. Incidencia, mortalidad y prevalencia de
Cáncer en Colombia 2007 - 2011. Inst Nac Cancerol [Internet]. 2015 [cited
2018 Mar 22];1:148. Available from:
http://www.cancer.gov.co/files/libros/archivos/incidencia1.pdf | spa |
dc.relation.references | INSTITUTO NACIONAL DE CANCEROLOGÍA. El cáncer de mama: un
problema creciente en Colombia. 2012 [cited 2018 Mar 22];4. Available
from:
http://www.cancer.gov.co/files/libros/archivos/95685f345e64aa9f0fece8a
589b5acc3_BOLETIN HECHOS Y ACCIONES MAMA.PDF | spa |
dc.relation.references | ersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and
therapeutic implications. World J Clin Oncol [Internet]. 2014 Aug 10 [cited
2018 Feb 20];5(3):412–24. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25114856 | spa |
dc.relation.references | A. Merino Bonillaa,∗ MTT y LHRM. El cáncer de mama en el siglo XXI: de la
detección precoz a los nuevos tratamientos. Radiologia [Internet]. 2017 Sep
1 [cited 2017 Oct 12];59(5):368–79. Available from:
http://www.sciencedirect.com/science/article/pii/S003383381730 | spa |
dc.relation.references | Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, et al. Biologic
and Clinical Characteristics of Breast Cancer With Single Hormone
Receptor–Positive Phenotype. J Clin Oncol [Internet]. 2007 Oct 20 [cited
2018 Mar 13];25(30):4772–8. Available from:
http://ascopubs.org/doi/10.1200/JCO.2007.12.2747 | spa |
dc.relation.references | Sotiriou C, Pusztai L. Gene-Expression Signatures in Breast Cancer. N Engl
J Med [Internet]. 2009 Feb 19 [cited 2018 Mar 8];360(8):790–800.
Available from: http://www.nejm.org/doi/abs/10.1056/NEJMra0801289 | spa |
dc.relation.references | Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. N Engl
J Med [Internet]. 2010 Nov 11 [cited 2018 Mar 13];363(20):1938–48.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/21067385 | spa |
dc.relation.references | Bourgeois-Daigneault M-C, Roy DG, Aitken AS, El Sayes N, Martin NT,
Varette O, et al. Neoadjuvant oncolytic virotherapy before surgery
sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci
Transl Med [Internet]. 2018 Jan 3 [cited 2018 Jul 29];10(422):eaao1641.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/29298865 | spa |
dc.relation.references | Arrechea Irigoyen MA, Vicente García F, Córdoba Iturriagagoitia A, Ibáñez
Beroiz B, Santamaría Martínez M, Guillén Grima F. Subtipos moleculares del
cáncer de mama: implicaciones pronósticas y características clínicas e
inmunohistoquímicas. An Sist Sanit Navar [Internet]. 2011 Aug [cited 2018
Mar 13];34(2):219–33. Available from:
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1137-
66272011000200008&lng=en&nrm=iso&tlng=en | spa |
dc.relation.references | Escrivá-de-Romaní S, Arumí M, Bellet M, Saura C. HER2-positive breast
cancer: Current and new therapeutic strategies. The Breast [Internet]. 2018
Jun 1 [cited 2018 Jul 29];39:80–8. Available from:
https://www.sciencedirect.com/science/article/pii/S0960977618300547 | spa |
dc.relation.references | Loibl S, Gianni L. HER2-positive breast cancer. Lancet [Internet]. 2017 Jun
17 [cited 2018 Jul 29];389(10087):2415–29. Available from:
https://www.sciencedirect.com/science/article/pii/S0140673616324175 | spa |
dc.relation.references | Martín M, Herrero A, Echavarría I, Echavarría I. El cáncer de mama. Arbor
[Internet]. 2015 Jun 30 [cited 2018 Mar 8];191(773):a234. Available from:
http://arbor.revistas.csic.es/index.php/arbor/article/view/2037/2530 | spa |
dc.relation.references | Alonso Castellanos S, Soto Célix M, Alonso Galarreta J, Riego Valledor A del,
Miján de la Torre A. Efectos adversos metabólicos y nutricionales asociados
a la terapia biológica del cáncer. Nutr Hosp [Internet]. 2014 [cited 2018
Mar 22];29(2):259–68. Available from:
http://scielo.isciii.es/scielo.php?pid=S0212-
16112014000200004&script=sci_arttext&tlng=pt | spa |
dc.relation.references | Eisenberg DP, Adusumilli PS, Hendershott KJ, Chung S, Yu Z, Chan M-K, et
al. Real-time intraoperative detection of breast cancer axillary lymph node
metastases using a green fluorescent protein-expressing herpes virus. Ann
Surg [Internet]. 2006 Jun [cited 2018 Jul 29];243(6):824-30-2. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/16772786 | spa |
dc.relation.references | Zhang W, Ge K, Zhao Q, Zhuang X, Deng Z, Liu L, et al. A novel oHSV-1
targeting telomerase reverse transcriptase-positive cancer cells via tumorspecific promoters regulating the expression of ICP4. Oncotarget [Internet].
2015 Aug 21 [cited 2018 Aug 20];6(24):20345–55. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25972362 | spa |
dc.relation.references | Teshigahara O, Goshima F, Takao K, Kohno S, Kimata H, Nakao A, et al.
Oncolytic viral therapy for breast cancer with herpes simplex virus type 1
mutant HF 10. J Surg Oncol [Internet]. 2004 Jan [cited 2018 Jul
29];85(1):42–7. Available from: http://doi.wiley.com/10.1002/jso.20005 | spa |
dc.relation.references | Kimata H, Imai T, Kikumori T, Teshigahara O, Nagasaka T, Goshima F, et al.
Pilot Study of Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus
(HF10) Against Recurrent Metastatic Breast Cancer. Ann Surg Oncol
[Internet]. 2006 Aug 24 [cited 2018 Jul 29];13(8):1078–84. Available
from: http://www.springerlink.com/index/10.1245/ASO.2006.08.03 | spa |
dc.relation.references | Marcato P, Dean CA, Giacomantonio CA, Lee PW. Oncolytic Reovirus
Effectively Targets Breast Cancer Stem Cells. Mol Ther [Internet]. 2009 Jun
1 [cited 2018 Jul 29];17(6):972–9. Available from:
https://www.sciencedirect.com/science/article/pii/S1525001616318032 | spa |
dc.relation.references | Dong X, Qu W, Ma S, Zhu Z, Zheng C, He A, et al. Potent antitumoral effects
of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for
breast cancer in vitro and in vivo. Cancer Lett [Internet]. 2013 Jan 1 [cited
2018 Aug 20];328(1):95–103. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/2300051 | spa |
dc.relation.references | ang Y, Xu W, Neill T, Hu Z, Wang C-H, Xiao X, et al. Systemic Delivery of
an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast
Cancer Bone Metastases. Hum Gene Ther [Internet]. 2015 Dec 14 [cited
2018 Aug 20];26(12):813–25. Available from:
http://www.liebertpub.com/doi/10.1089/hum.2015.098 | spa |
dc.relation.references | Sarkar S, Quinn BA, Shen X-N, Dash R, Das SK, Emdad L, et al. Therapy of
prostate cancer using a novel cancer terminator virus and a small molecule
BH-3 mimetic. Oncotarget [Internet]. 2015 May 10 [cited 2018 Aug
20];6(13):10712–27. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/25926554 | spa |
dc.relation.references | Wang H, Chen NG, Minev BR, Szalay AA. Oncolytic vaccinia virus GLV-1h68
strain shows enhanced replication in human breast cancer stem-like cells in
comparison to breast cancer cells. J Transl Med [Internet]. 2012 Aug 17
[cited 2018 Jul 29];10(1):167. Available from: http://translationalmedicine.biomedcentral.com/articles/10.1186/1479-5876-10-167 | spa |
dc.relation.references | Seubert CM, Stritzker J, Hess M, Donat U, Sturm JB, Chen N, et al. Enhanced
tumor therapy using vaccinia virus strain GLV-1h68 in combination with a
β-galactosidase-activatable prodrug seco-analog of duocarmycin SA.
Cancer Gene Ther [Internet]. 2011 Jan [cited 2018 Aug 20];18(1):42–52.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/20829890 | spa |
dc.relation.references | Pugalenthi A, Mojica K, Ady JW, Johnsen C, Love D, Chen NG, et al.
Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the
treatment of cholangiocarcinoma. Cancer Gene Ther [Internet]. 2015 Dec
20 [cited 2018 Aug 20];22(12):591–6. Available from:
http://www.nature.com/articles/cgt201560 | spa |
dc.relation.references | Geekiyanage H, Galanis E. MiR-31 and miR-128 regulates poliovirus
receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol
[Internet]. 2016 Nov [cited 2018 Aug 20];10(9):1387–403. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/27507538 | spa |
dc.relation.references | Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D. Targeting
CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor
vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S
A [Internet]. 2013 Apr 2 [cited 2018 Jul 29];110(14):E1291-300. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/23509246 | spa |
dc.relation.references | Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, et al.
Intravenous administration of Reolysin®, a live replication competent RNA
virus is safe in patients with advanced solid tumors. Invest New Drugs
[Internet]. 2010 Oct 2 [cited 2018 Aug 20];28(5):641–9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/19572105 | spa |
dc.relation.references | Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG,
DiFrancesco LM, et al. Reovirus Oncolysis of Human Breast Cancer.
https://home.liebertpub.com/hum [Internet]. 2004 Jul 6 [cited 2018 Jul
29]; Available from:
https://www.liebertpub.com/doi/abs/10.1089/10430340252837233 | spa |
dc.relation.references | Duchnowska R, Loibl S, Jassem J. Tyrosine kinase inhibitors for brain
metastases in HER2-positive breast cancer. Cancer Treat Rev [Internet].
2018 Jun 1 [cited 2018 Jul 29];67:71–7. Available from:
https://www.sciencedirect.com/science/article/pii/S0305737218300677 | spa |
dc.relation.references | Le Boeuf F, Selman M, Son HH, Bergeron A, Chen A, Tsang J, et al. Oncolytic
Maraba Virus MG1 as a Treatment for Sarcoma. Int J Cancer [Internet].
2017 Sep 15 [cited 2018 Aug 20];141(6):1257–64. Available from:
http://doi.wiley.com/10.1002/ijc.30813 | spa |
dc.relation.references | Janke M, Peeters B, de Leeuw O, Moorman R, Arnold A, Fournier P, et al.
Recombinant Newcastle disease virus (NDV) with inserted gene coding for
GM-CSF as a new vector for cancer immunogene therapy. Gene Ther
[Internet]. 2007 Dec 4 [cited 2018 Aug 20];14(23):1639–49. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/17914407 | spa |
dc.relation.references | Ju J, Zhu A-J, Yuan P. Progress in targeted therapy for breast cancer. Chronic
Dis Transl Med [Internet]. 2018 Jul 7 [cited 2018 Jul 29]; Available from:
https://www.sciencedirect.com/science/article/pii/S2095882X18300069 | spa |
dc.relation.references | Hamano S, Mori Y, Aoyama M, Kataoka H, Tanaka M, Ebi M, et al. Oncolytic
reovirus combined with trastuzumab enhances antitumor efficacy through
TRAIL signaling in human HER2-positive gastric cancer cells. Cancer Lett
[Internet]. 2015 Jan 28 [cited 2018 Aug 20];356(2):846–54. Available
from:
https://www.sciencedirect.com/science/article/pii/S0304383514006806 | spa |
dc.relation.references | Li J, Zeng W, Huang Y, Zhang Q, Hu P, Rabkin SD, et al. Treatment of breast
cancer stem cells with oncolytic herpes simplex virus. Cancer Gene Ther
[Internet]. 2012 Oct 17 [cited 2018 Jul 29];19(10):707–14. Available from:
http://www.nature.com/articles/cgt201249 | spa |
dc.relation.references | Seth P, Wang Z-G, Pister A, Zafar MB, Kim S, Guise T, et al. Development
of Oncolytic Adenovirus Armed with a Fusion of Soluble Transforming
Growth Factor-β Receptor II and Human Immunoglobulin Fc for Breast
Cancer Therapy. Hum Gene Ther [Internet]. 2006 Nov 16 [cited 2018 Jul
29];17(11):1152–61. Available from:
http://www.liebertonline.com/doi/abs/10.1089/hum.2006.17.1152 | spa |
dc.relation.references | Zhu W, Zhang H, Shi Y, Song M, Zhu B, Wei L. Oncolytic adenovirus encoding
tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the
growth and metastasis of triple-negative breast cancer. Cancer Biol Ther
[Internet]. 2013 Nov [cited 2018 Aug 20];14(11):1016–23. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/24025362 | spa |
dc.rights.accessrights | info:eu-repo/semantics/closedAccess | spa |
dc.rights.creativecommons | Atribución-NoComercial-CompartirIgual 4.0 Internacional (CC BY-NC-SA 4.0) | spa |
dc.subject.lemb | Virus naturales | |
dc.subject.lemb | Células | |
dc.subject.lemb | Cáncer | |
dc.subject.proposal | Cáncer | spa |
dc.subject.proposal | Respuesta inmune | spa |
dc.subject.proposal | Virus oncolíticos | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_7a1f | spa |
dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
dc.type.content | Text | spa |
dc.type.driver | info:eu-repo/semantics/bachelorThesis | spa |
dc.type.redcol | https://purl.org/redcol/resource_type/TP | spa |
dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
dc.rights.coar | http://purl.org/coar/access_right/c_14cb | spa |